超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

以色列Procognia? ?
Procognia (Israel) Ltd is a renowned leader in the growing field of glycobiology, specifically in glycoanalysis. Publicly traded on the TASE (symbol: PRCG), Procognia is recognized for its state-of-the-art proprietary tools and high end platforms, providing fast and accurate glycoanalysis of glycoproteins. The company is located in Minrav Hi-Tech Park, Ashdod, Israel.

?

In glycoanalysis, technical skills alone are not always sufficient to achieve the desired results. Consequently, glycoanalysis is often characterized as an "art", as opposed to a technical procedure. Since its establishment in 2000, Procognia has acquired extensive knowledge and broad experience in all aspects of glycoanalysis. The company has developed its own proprietary technological platform, as well as attaining expertise in the use of existing technologies (HPLC, MS). Procognia is well equipped to provide a comprehensive solution for the entire world of glycoanalysis in a range of applications, such as: process development & manufacturing of biopharmaceuticals, life science & pharma research, glycodiagnostic & biomarker tools, stem cells and food applications.

?

Today, Procognia is moving forward with profound industry knowledge and a strong record of success, leveraging the unique advantages of high throughput glycoanalysis for many different applications. To this end, the company has developed a number of unique products based on its technological platform: GlycoscopeTM, QproteomeTM . These provide a range of analytical approaches, from qualitative analysis to comprehensive, accurate quantitative insight.

?

Procognia has established several international partnership agreements, including the worldwide exclusive license for high expression clone technology. Procognia's joint ventures and global team provide an extra added-value for customers, utilizing state-of-the-art technologies for industrial biotechnology companies as well as within the academia.

?

Through this unified collaboration, Procognia creates tailor-made development packages, offering a streamlined synergistic approach for low risk and efficient development of high quality biosimilar drugs, from clone generation through to purified bulk product for pre-clinical studies.

?